Medicxi

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It is dedicated to discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. The company employs a proprietary discovery and development engine to create highly selective small molecules that modulate immune responses related to these conditions. RAPT has advanced two notable drug candidates: FLX475, which targets the inhibition of immunosuppressive regulatory T cells in tumors, and RPT193, which selectively inhibits type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short timeframe since the company's inception. Additionally, RAPT is exploring several other targets in the discovery phase, including general control nonderepressible 2 and hematopoietic progenitor kinase 1.

Ottimo Pharma is a biopharmaceutical company dedicated to developing innovative cancer therapies for solid tumors. Its primary focus is Jankistomig, a bi-functional antibody that simultaneously targets two critical pathways in cancer growth: immune checkpoint inhibition and angiogenesis. By addressing these pathways concurrently, Ottimo Pharma aims to improve treatment outcomes and reduce the burden of cancer on patients and the healthcare system.

Ottimo Pharma is a biopharmaceutical company dedicated to developing innovative cancer therapies for solid tumors. Its primary focus is Jankistomig, a bi-functional antibody that simultaneously targets two critical pathways in cancer growth: immune checkpoint inhibition and angiogenesis. By addressing these pathways concurrently, Ottimo Pharma aims to improve treatment outcomes and reduce the burden of cancer on patients and the healthcare system.

ViceBio is a biopharmaceutical company focused on developing innovative vaccines to combat respiratory viral infections. Utilizing its patented Molecular Clamp Technology, the company stabilizes viral glycoproteins in a prefusion conformation, which allows for the creation of effective and ready-to-use fully liquid vaccines. This technology facilitates the long-term storage and convenient administration of vaccines targeting a range of respiratory viruses, including respiratory syncytial virus (RSV), metapneumovirus, influenza, and SARS-CoV-2. By prioritizing the prevention of potentially fatal respiratory illnesses, ViceBio aims to significantly enhance public health outcomes.

D3 Bio, established in 2020, is a biotechnology company headquartered in China. It specializes in the development and registration of innovative medicines, primarily focusing on oncology and immunology. The company's approach involves analyzing clinical and market data to identify gaps in current treatments, employing unique drug development methodologies to target new disease areas and routes, and ultimately providing patients with alternative therapeutic options.

ProfoundBio is a clinical-stage biotechnology company dedicated to creating novel antibody-based therapeutics aimed at treating cancer. The company utilizes innovative proprietary technology platforms to develop a diverse pipeline of antibody-drug conjugate (ADC) candidates that target both solid tumors and hematological malignancies. These drug candidates are currently in various stages of discovery, preclinical, and clinical development. ProfoundBio's focus on advancing targeted therapeutics leverages the immune system's capabilities to potentially eradicate cancer, offering improved treatment options with curative potential for patients.

Alys Pharmaceuticals is a company dedicated to advancing immuno-dermatology services through innovative scientific research and development. By strategically aggregating six asset-centric companies, Alys aims to transform treatment paradigms for various dermatological conditions. Its multi-platform pipeline is designed to optimize the impact of its diverse asset classes, enabling the healthcare industry to access transformative solutions for a wide range of dermatological indications. Through a strong focus on research and development, Alys Pharmaceuticals is reshaping the treatment landscape in the field of dermatology.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.

Aldena Therapeutics is a private biotechnology startup focused on developing innovative treatments for dermatological conditions using siRNA-based therapies. The company specializes in microneedle technology that delivers medicinal skin creams containing microscopic STAR particles, which are designed to facilitate the administration of nucleic acid therapies. This approach aims to address various skin conditions that pose significant challenges for patients, offering a novel solution with the potential for improved therapeutic outcomes.

NewAmsterdam Pharma, established in 2019 and headquartered in Naarden, the Netherlands, is a late-stage biopharmaceutical company dedicated to improving patient care in cardio-metabolic disease populations. The company's primary focus is the development of transformative therapies, with its lead product, obicetrapib, being a next-generation, oral, low-dose CETP inhibitor designed to lower LDL-C levels more effectively than current treatments, particularly for patients with statin intolerance or Arteriosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally-tolerated statin therapy.

Rivus Pharmaceuticals is a biopharmaceutical company focused on enhancing cardio-metabolic health through the development of controlled metabolic accelerators (CMAs). These innovative therapeutics are designed to improve cellular metabolism and target the root causes of prevalent metabolic and cardiovascular diseases. By addressing the underlying metabolic risk factors associated with cardiovascular mortality and morbidity, Rivus aims to provide effective oral small-molecule treatments for patients suffering from these conditions.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

Xenikos is a biopharmaceutical company focused on developing innovative immunotherapy treatments aimed at restoring health to patients suffering from serious immune diseases and transplant rejection. The company specializes in creating anti-T-cell antibodies that act as a therapeutic tool to reset the immune system. Once administered, these antibodies specifically target and eliminate activated adult T cells, allowing for improved treatment outcomes in various medical conditions. By harnessing the potential of antibody action, Xenikos aims to provide efficient solutions that can significantly enhance patient recovery and overall well-being.

Versanis Bio is a biopharmaceutical company focused on discovering and developing innovative medicines for medical conditions commonly affecting older adults. The company is advancing Bimagrumab, a human monoclonal antibody that targets activin type II receptors, effectively blocking ligands such as activin A and myostatin. Bimagrumab has undergone extensive clinical evaluation in over a dozen trials with more than 1,500 participants, demonstrating its ability to induce significant fat loss while preserving lean mass. Additionally, treatment with Bimagrumab has shown improvements in HbA1c levels and other cardiometabolic parameters, thereby assisting overweight and obese adults in achieving and maintaining a healthier body composition.

Sydnexis is a biopharmaceutical company focused on developing a proprietary treatment for pediatric progressive myopia, which represents a significant unmet medical need globally. The company specializes in manufacturing a topical eyedrop formulation aimed at slowing the progression of myopia in children. By providing an innovative solution, Sydnexis enables healthcare professionals and institutions to effectively manage and reduce the incidence of myopia-related eye disorders in the pediatric population.

Rivus Pharmaceuticals is a biopharmaceutical company focused on enhancing cardio-metabolic health through the development of controlled metabolic accelerators (CMAs). These innovative therapeutics are designed to improve cellular metabolism and target the root causes of prevalent metabolic and cardiovascular diseases. By addressing the underlying metabolic risk factors associated with cardiovascular mortality and morbidity, Rivus aims to provide effective oral small-molecule treatments for patients suffering from these conditions.

Kurome Therapeutics, Inc. is a preclinical stage biotechnology company based in Cincinnati, Ohio, focused on developing innovative therapies for cancer treatment. Founded in 2019, the company specializes in targeting cancer cells that have hijacked immune signaling pathways to evade destruction by conventional therapies. By developing inhibitors that specifically address over-activated IRAK1/4-mediated signaling pathways, Kurome Therapeutics aims to disrupt the mechanisms that allow cancer cells to survive and resist treatment. Its approach is particularly relevant for hematological cancers, as it seeks to enhance the effectiveness of existing therapies and improve patient outcomes.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies aimed at targeting and destroying cancer cells through viral nanoparticle conjugates. The company's lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary cancer of the eye. Aura Biosciences aims to address the challenges of treating small ocular melanomas early in the disease progression to prevent metastasis, particularly to the liver, which is often fatal. In addition to ocular oncology, the company is exploring applications of its platform in other indications, including bladder cancer. Founded in 2007, Aura Biosciences is committed to advancing precision immunotherapies designed to preserve organ function while effectively managing a range of solid tumors.

SynOx Therapeutics is a clinical stage biopharmaceutical company based in Dublin, Ireland, established in 2019. The company focuses on the development of innovative therapies for cancer, particularly through its lead product, emactuzumab. This humanized monoclonal antibody specifically targets the CSF-1 receptor, aiming to deplete macrophages within tumor tissues. SynOx Therapeutics is dedicated to addressing the unmet clinical needs of patients suffering from diffuse tenosynovial giant cell tumors and other conditions associated with macrophage activity, ultimately striving to provide best-in-class treatment options that enhance patient quality of life. The company is backed by experienced investors with a strong track record in biopharmaceutical development.

Janpix Ltd. is a biopharmaceutical company focused on developing targeted cancer therapies through the inhibition of Signal Transducer and Activator of Transcription (STAT) proteins. Founded in 2017 and headquartered in Cambridge, Massachusetts, with a research facility in Mississauga, Canada, Janpix specializes in the discovery of inhibitors for multiple STAT proteins, including STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6, and STAT3/5. The company is particularly noted for its research on the role of certain STAT proteins, especially STAT3 and STAT5, in cancer, specifically in hematological tumors and glioblastomas. Janpix has developed novel chemistry solutions to effectively target and inhibit the function of these proteins, aiming to modulate immune responses and improve the tumor microenvironment to facilitate cancer eradication and provide patients with better therapeutic options.

Palladio Biosciences, Inc. is a biotechnology company focused on developing innovative medicines for orphan kidney diseases. Established in 2015 and headquartered in Horsham, Pennsylvania, the company is primarily engaged in creating therapeutics for conditions such as polycystic kidney disease (PKD), a serious genetic disorder characterized by the formation of fluid-filled cysts in the kidneys. One of its key products, Lixivaptan, is a selective vasopressin V2 receptor antagonist aimed at treating PKD, helping to prevent disease progression and improve patient outcomes. Palladio Biosciences is dedicated to addressing unmet medical needs in the field of renal diseases.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

Vaxcyte, Inc. is a preclinical-stage biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. Headquartered in Foster City, California, Vaxcyte's lead candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company is also advancing VAX-XP, which aims to address emerging strains of pneumococcal disease and antibiotic resistance. Additionally, Vaxcyte is developing VAX-A1, a conjugate vaccine for Group A Streptococcus, and VAX-PG, a novel therapeutic vaccine targeting periodontal disease. Utilizing a proprietary cell-free protein synthesis platform, Vaxcyte designs and produces the essential components of vaccines, enhancing their efficacy compared to traditional technologies. Founded in 2013 and originally named SutroVax, Vaxcyte rebranded in May 2020 to reflect its commitment to improving global health through superior vaccine development.

Alderaan Biotechnology is a biotechnology company focused on developing innovative antibodies aimed at treating cancer. The company specializes in monoclonal antibodies that target specific immune cells, particularly Natural Killer (NK) cells and regulatory T (Treg) cells within the tumor microenvironment. These antibodies are designed to deplete Treg cells and enhance the cytotoxic activity of NK cells, representing a novel approach in immuno-oncology. By providing new immunotherapy options, Alderaan Biotechnology enables physicians to better address the complexities of cancer treatment through targeted immune modulation.

Vaderis Therapeutics is a biotechnology company focused on developing oral medications for the treatment of rare and orphan diseases, particularly those associated with vascular malformations. The company is currently in the clinical stages of its product development, with a specific emphasis on addressing hereditary hemorrhagic telangiectasia (HHT). Vaderis Therapeutics aims to alleviate the symptoms of HHT and reduce the occurrence of new lesions, thereby enabling healthcare providers to better manage the disease's progression. Through its innovative approach, the company seeks to improve the quality of life for patients affected by these uncommon conditions.

Divide & Conquer is a biotechnology company based in Cambridge, United Kingdom, specializing in the development and manufacturing of therapeutics for various types of cancers, particularly glioblastoma, a highly aggressive form of brain cancer. Founded in 2018, the company focuses on creating small molecule drugs that disrupt cell-to-cell communication within tumors, targeting malignant cellular networks and related structures such as tumor microtubes and tunneling nanotubes. Through collaborations with esteemed institutions like the University of Heidelberg and the German Cancer Research Center, Divide & Conquer aims to develop innovative treatments for glioblastoma, breast cancer, pancreatic cancer, prostate cancer, lung cancer, and colorectal cancer, addressing conditions with poor life expectancy.

Breakpoint Therapeutics GmbH, based in Hamburg, Germany, is dedicated to the discovery and development of innovative anti-cancer drugs. The company focuses on targeting the DNA damage response (DDR) in cancer cells, aiming to create first-in-class oncology drugs that disrupt DNA repair mechanisms and replication stress tolerance pathways. By developing therapeutics that complement existing treatments, such as PARP inhibitors, Breakpoint Therapeutics seeks to address the challenges posed by therapy-resistant cancers, ultimately striving to improve patient outcomes in oncology.

Yukin Therapeutics is a French biotechnology company specializing in the development of innovative therapeutic molecules, particularly kinase inhibitors targeting the NIK protein, which plays a crucial role in the progression of various cancers. The company has conducted studies demonstrating proof of concept in animal models, showcasing the potential of its proprietary molecules to alter the tumor microenvironment. This alteration enhances the immune system's ability to infiltrate and eliminate tumors, thereby improving the efficacy of existing cancer immunotherapies. Yukin Therapeutics is currently focused on identifying a first drug candidate to advance into clinical trials, with the aim of addressing multiple cancer types, including skin and pancreatic cancers.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, that specializes in developing and commercializing innovative treatments for gastrointestinal diseases. Incorporated in 2018, the company has rights in the United States, Europe, and Canada for vonoprazan, a potassium-competitive acid blocker (P-CAB) designed to inhibit acid secretion in the stomach. Currently, vonoprazan is undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being evaluated in combination with antibiotics for addressing Helicobacter pylori infection. Phathom Pharmaceuticals aims to meet the unmet medical needs of patients suffering from acid-related disorders by leveraging the expertise of its team, which comprises seasoned professionals from the gastrointestinal and pharmaceutical sectors.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies aimed at targeting and destroying cancer cells through viral nanoparticle conjugates. The company's lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary cancer of the eye. Aura Biosciences aims to address the challenges of treating small ocular melanomas early in the disease progression to prevent metastasis, particularly to the liver, which is often fatal. In addition to ocular oncology, the company is exploring applications of its platform in other indications, including bladder cancer. Founded in 2007, Aura Biosciences is committed to advancing precision immunotherapies designed to preserve organ function while effectively managing a range of solid tumors.

Orexia Limited is a biopharmaceutical company based in London, United Kingdom, focused on developing innovative therapies for neurological diseases. Founded in 2018, the company specializes in creating oral orexin positive modulators aimed at treating narcolepsy, a rare neurological condition that disrupts the brain's regulation of the sleep-wake cycle. By targeting G protein-coupled receptors Orexin OX1 and OX2, Orexia's therapies aim to restore normal orexin levels in the brain, offering potential relief from the symptoms associated with narcolepsy.

Inexia Limited is a biotechnology company based in London, United Kingdom, founded in 2018. The company specializes in developing novel therapies using positive modulators of the G protein-coupled receptors Orexin OX1 and OX2, targeting neurological diseases. Inexia focuses on creating intranasally administered orexin positive modulators specifically for the treatment of narcolepsy, a condition linked to the loss of orexin neurons. By leveraging an innovative exhalation delivery system, Inexia's therapies aim to restore orexin levels in the brain, thereby alleviating symptoms associated with narcolepsy. The intact and functional orexin receptors present in patients offer a promising opportunity for therapeutic intervention in this area.

Morphogen-IX Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative treatments for pulmonary arterial hypertension (PAH), a severe and life-limiting condition that affects lung blood vessels and can lead to heart failure. Founded in 2015, Morphogen-IX is pioneering the use of bone morphogenetic proteins, particularly BMP9 and BMP10, to enhance BMPR-II receptor signaling in endothelial cells, which is crucial for addressing the underlying mechanisms of PAH. Current therapies primarily alleviate symptoms rather than addressing the disease's root causes, leaving patients with limited options. The company employs a semi-virtual model, leveraging a network of experienced professionals in drug discovery to maximize capital efficiency while maintaining high-quality research and development.

Vaxcyte, Inc. is a preclinical-stage biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. Headquartered in Foster City, California, Vaxcyte's lead candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company is also advancing VAX-XP, which aims to address emerging strains of pneumococcal disease and antibiotic resistance. Additionally, Vaxcyte is developing VAX-A1, a conjugate vaccine for Group A Streptococcus, and VAX-PG, a novel therapeutic vaccine targeting periodontal disease. Utilizing a proprietary cell-free protein synthesis platform, Vaxcyte designs and produces the essential components of vaccines, enhancing their efficacy compared to traditional technologies. Founded in 2013 and originally named SutroVax, Vaxcyte rebranded in May 2020 to reflect its commitment to improving global health through superior vaccine development.

Xenikos is a biopharmaceutical company focused on developing innovative immunotherapy treatments aimed at restoring health to patients suffering from serious immune diseases and transplant rejection. The company specializes in creating anti-T-cell antibodies that act as a therapeutic tool to reset the immune system. Once administered, these antibodies specifically target and eliminate activated adult T cells, allowing for improved treatment outcomes in various medical conditions. By harnessing the potential of antibody action, Xenikos aims to provide efficient solutions that can significantly enhance patient recovery and overall well-being.

Synthorx, Inc. is a biopharmaceutical company specializing in the development of innovative protein therapeutics using advanced synthetic biology techniques. Founded in 2014 and headquartered in La Jolla, California, Synthorx focuses on its proprietary Synthorin programs aimed at treating cancer and autoimmune disorders. Its lead product candidate, THOR-707, is a modified form of recombinant human IL-2, currently being evaluated for various solid tumors both as a standalone treatment and in combination with immune checkpoint inhibitors. The company also develops Synthorins targeting IL-2 for autoimmune conditions, IL-10 for immuno-oncology applications, and IL-15 for regulating immune responses. Synthorx leverages a unique platform that enables the incorporation of synthetic DNA base pairs to enhance the specificity and efficacy of its protein therapeutics, thus offering improved treatment options for patients. Previously known as Alinos, Inc., the company acquired exclusive rights to its synthetic biology technology based on groundbreaking research from The Scripps Research Institute. As of January 2020, Synthorx operates as a subsidiary of Sanofi.

Critical Pressure specializes in developing innovative drugs aimed at treating vascular dysfunction and shock. The company's technology offers a novel approach to clinical practice by mitigating the harmful effects associated with excess fluid administration and the toxicities linked to traditional catecholamine-based vasoactive agents. This advancement enables the provision of supportive therapy during critical periods of hemodynamic compromise, positioning Critical Pressure as a significant player in enhancing patient care in acute medical situations.

Impact Biomedicines, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative treatments for patients with myeloproliferative neoplasms and other cancers. Founded in 2016 and headquartered in San Diego, California, the company is primarily centered on its lead product, fedratinib, a potent and selective oral small molecule JAK2 kinase inhibitor. Fedratinib is being developed for the treatment of myelofibrosis and polycythemia vera, with additional potential applications in acute myeloid leukemia and colorectal cancer. As of February 2018, Impact Biomedicines operates as a subsidiary of Bristol-Myers Squibb Company.

Janpix Ltd. is a biopharmaceutical company focused on developing targeted cancer therapies through the inhibition of Signal Transducer and Activator of Transcription (STAT) proteins. Founded in 2017 and headquartered in Cambridge, Massachusetts, with a research facility in Mississauga, Canada, Janpix specializes in the discovery of inhibitors for multiple STAT proteins, including STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6, and STAT3/5. The company is particularly noted for its research on the role of certain STAT proteins, especially STAT3 and STAT5, in cancer, specifically in hematological tumors and glioblastomas. Janpix has developed novel chemistry solutions to effectively target and inhibit the function of these proteins, aiming to modulate immune responses and improve the tumor microenvironment to facilitate cancer eradication and provide patients with better therapeutic options.

Sydnexis is a biopharmaceutical company focused on developing a proprietary treatment for pediatric progressive myopia, which represents a significant unmet medical need globally. The company specializes in manufacturing a topical eyedrop formulation aimed at slowing the progression of myopia in children. By providing an innovative solution, Sydnexis enables healthcare professionals and institutions to effectively manage and reduce the incidence of myopia-related eye disorders in the pediatric population.

Diasome Pharmaceuticals, Inc. is a clinical stage diabetes therapeutics company focused on designing and developing innovative insulin-based therapies for the treatment of Type 1 and Type 2 diabetes. Founded in 2004, the company is headquartered in Cleveland, Ohio. Diasome's flagship product, the hepatocyte directed vesicle (HDV), is a nanoscale carrier that delivers multiple insulin molecules directly to the liver and is compatible with all commercially available insulin delivery methods, including insulin pumps. The company also offers Oral HVD-I, a targeted oral insulin in pill or gel cap form, and injectable insulin options such as HDV-I, a short-acting formulation, and HDV-B, a long-acting formulation. Through its proprietary technology, Diasome aims to improve glycemic control and optimize insulin delivery systems for diabetes patients.

Palladio Biosciences, Inc. is a biotechnology company focused on developing innovative medicines for orphan kidney diseases. Established in 2015 and headquartered in Horsham, Pennsylvania, the company is primarily engaged in creating therapeutics for conditions such as polycystic kidney disease (PKD), a serious genetic disorder characterized by the formation of fluid-filled cysts in the kidneys. One of its key products, Lixivaptan, is a selective vasopressin V2 receptor antagonist aimed at treating PKD, helping to prevent disease progression and improve patient outcomes. Palladio Biosciences is dedicated to addressing unmet medical needs in the field of renal diseases.

Z Factor Limited is a drug discovery company established in 2015 with a focus on developing therapeutic agents for alpha-1-antitrypsin deficiency. Founded through a collaboration between Index Ventures and the University of Cambridge, the company is dedicated to designing innovative treatments that address the misfolding of the Z variant of alpha-1-antitrypsin. This condition presents significant medical challenges, and current treatment options are largely restricted to lung or liver transplantation and augmentation therapy. By targeting the underlying causes of the disease, Z Factor aims to fulfill a critical unmet medical need in the field of respiratory and liver health.

SuperX is a preclinical biopharmaceutical company based at the Babraham Research Campus, focused on developing novel anticoagulant therapies. The company is engaged in the discovery of antibodies targeting components of the blood coagulation cascade, aiming to create anti-thrombotic drugs that reduce the risk of bleeding. By specifically blocking thrombosis, which is a leading cause of heart attacks and strokes, SuperX seeks to provide healthcare institutions and physicians with effective anticoagulation treatments suitable for chronic use. Through its innovative approach, the company aspires to improve patient outcomes in the management of cardiovascular diseases.

ApcinteX is a biotechnology company focused on developing and marketing innovative therapies for hemophilia. The company has created a novel anticoagulant protein therapy that aims to modulate a critical natural anticoagulant pathway, promoting normal blood clotting in hemophilia patients. This treatment is designed to be effective for all hemophilia types, including cases where patients develop antibodies against traditional replacement factors. ApcinteX's therapy has the added benefit of not inducing anti-clotting antibodies, and it can be administered easily through a simple subcutaneous injection every two weeks.

Mavalon Therapeutics is a company focused on stopping the progression of Parkinson’s disease. The biotechnology company is developing mGluR3 allosteric modulators for the treatment of Parkinson's disease.

Kymo Therapeutics’s ambition is to move forward Metabrain Research’s proprietary program on kynurenine metabolism (KMO) inhibitors towards clinical proof of concept, before seeking partners to complete development and ensure commercialization.

Gadeta is a research and development company focused on creating innovative immunotherapies for cancer treatment. It has developed a technology platform that utilizes combinatorial T cell receptor exchange to produce optimized gamma delta T-cell receptors with enhanced anti-cancer properties. Gadeta’s primary product, T Cells Engineered To Express A Defined Gamma Delta TCR (TEGs), shows significant therapeutic potential for targeting and eliminating both hematological and solid tumors. The company's approach leverages high-affinity gamma delta TCRs expressed on alpha beta T cells, which possess superior proliferation capacity, aiming to improve outcomes for patients with advanced malignancies. Through its research, Gadeta seeks to contribute to the eradication of cancer and enhance treatment efficacy across various types of tumors.

Capella BioScience is engaged in the discovery and development of monoclonal antibodies (mAbs) for therapeutic applications. The company utilizes proprietary technologies to create and commercialize mAbs targeting oncology, autoimmune diseases, and other medical conditions. Capella BioScience collaborates with biotechnology firms and academic institutions to enhance its research and development efforts, aiming to advance innovative therapeutic solutions in the medical field.

Stealthyx Therapeutics Ltd. is a biotechnology company focused on developing an innovative drug-targeting platform technology designed to deliver therapeutic agents specifically to sites of disease. Founded in 2002 and based in Babraham, United Kingdom, the company’s proprietary Stealthyx platform utilizes a fusion protein that combines a protective shell-like structure with pharmacologically active agents linked through enzyme-sensitive cleavage sites. This mechanism allows for the targeted release of drugs in response to pathological processes, enhancing the efficacy of cytokines, small peptides, and antibody fragments while reducing toxicity. By improving the pharmacokinetic and pharmacodynamic properties of biological agents, Stealthyx Therapeutics aims to advance the field of drug delivery and enhance treatment outcomes.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.